News

ERC puts €680m into research
Enlarge image

FundingSwitzerlandEU

ERC puts €680m into research

24.01.2013 - The European Research Council (ERC) has awarded €680m to 302 top basic researchers in 24 EU countries.

The awards are part of the latest series of the ERC’s Advanced Grants, which give up to €2.5m per researcher to pursue ground-breaking ideas at the frontiers of knowledge. Life Science researchers were very successful in this call, bagging 37% of the total funding cake. However, at only 13%, the ERC grant’s success rate is very low compared to other funding programmes. The European Commission has proposed to expand the ERC's budget significantly in its 2014-2020 innovation programme Horizon 2020. Negotiations with the member states about the long-term EU budget including Horizon2020, however, were cancelled at the end of last year. This is why the ERC has now begun to extend its lobbying activities.

ERC representative Helga Nowotny, thus, for the first time attended the World Economic Forum (WEF) in Davos to embrace industry and policymakers. ”The health and wealth of future societies greatly depend on maintaining the long-term perspectives that science offers,“ said ERC chief Nowotny.."Investment in research, education and innovation is even more important in times of budgetary austerity, in Europe and elsewhere. Leaders from all fields, including business, understand this dynamic, but need to find novel ways of joining forces. We truly believe that science, as well as technology and innovation, will emerge as a common theme of interest to shape the agenda of the future decades”.

The idea to catalyse actions for putting science, technology and innovation on the global agenda has already started and is likely to be prominent in this year's forum. There is growing awareness amongst policy-makers worldwide and public research organisations, of the fact that globalisation of science offers unprecedented opportunities for cooperation. In Davos, one of the sessions will be devoted to how decision-makers, business, civil society and academia can join forces to build a new vision based on frontier research, scientific discoveries and innovation.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/erc-funds-researchers-with-eur680m.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2281.2%
  • TRANSGENE (F)5.08 EUR80.8%
  • TIGENIX (B)1.02 EUR30.8%

FLOP

  • THROMBOGENICS (B)2.90 EUR-42.9%
  • BIONOR PHARMA (N)1.28 NOK-37.6%
  • WILEX (D)2.05 EUR-36.5%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 29.08.2015